We embarked on a study to evaluate how vitamin D3 supplementation might influence hypertension, particularly among patients coping with COVID-19 and cardiovascular diseases. By involving 50 adult participants, we effectively organized them into two groups: one receiving daily doses of 10,000 IU of vitamin D3 and the other receiving a placebo.
Our findings revealed promising results for those taking vitamin D3. We observed an increase in the Ang-(1-7)/Ang II ratio, which suggests enhanced ACE2 activity, an important factor in heart and blood vessel function. Notably, patients treated with vitamin D3 experienced a significant decline in inflammatory markers, which often exacerbate hypertension.
Moreover, we noted a trend towards reductions in blood pressure levels among hypertensive patients in the vitamin D3 group. This suggests that vitamin D3 could play a role in better managing blood pressure, alongside potentially influencing overall recovery from COVID-19.
Overall, our research indicates that vitamin D3 supplementation may hold therapeutic promise for individuals with hypertension, especially during challenging times such as the COVID-19 pandemic.